

10. Literaturverzeichnis

Adams, L.B., Hibbs, J.B., Taintor, R.R., and Krahenbuhl, J. L. (1990) Microbiostatic effect of murine-activated macrophages for *Toxoplasma gondii*. Role for synthesis of inorganic nitrogen oxides from L-arginine, *J. Immunol.* 144, 2725

Alyautdin, R.N., Petrov, V.E., Langer, K., Berthold, A., Kharkevich, D.A., Kreuter, J. (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles, *Pharm. Res.*14(3), 325-328

Araujo, F.G., Remington, J.S. (1991) Synergistic activity of azithromycin and gamma interferon in murine toxoplasmosis, *Antimicrob. Agents Chemother.* 35, 293

Aspöck, H. (1995) Toxoplasmose bei Tieren. In: "Toxoplasmose - Erreger und Krankheit", Pohle, H. D.; Remington, J. S. (Hrsg.), Socio-medico Verlag, Gräfelfing, 2. Auflage, 24-29

Bauer, K., Frömming, K.-H., Führer, C. (1999) Lehrbuch der Pharmazeutischen Technologie. 6.Auflage, Wissenschaftliche Verlagsgesellschaft Stuttgart

Birrenbach, G., Speiser, P. (1976) Polymerized micelles and their use as adjuvants in immunology, *J. Pharm. Sci.* 65, 1763-1766

Black, M.W., Boothroyd, J.C. (2000) Lytic cycle of *Toxoplasma gondii*, *Microbiol. Mol. Biol. Rev.* 64, 607-623.

Bootz, A., Russ, T., Gores, F., Karas, M., Kreuter, J. (2005) Molecular weights of poly(butyl cyanoacrylate) nanoparticles determined by mass spectrometry and size exclusion chromatography, *Eur J Pharm Biopharm.* 60(3), 391-399

Brannon-Peppas, L. (1995) Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery, *Int. J. Pharm.* 116, 1-9

Brannon-Peppas, L., Blanchette, J.O. (2004) Nanoparticle and targeted systems for cancer therapy, *Adv. Drug Deliv. Rev.* 56, 1649-1659

10. Literaturverzeichnis

Bronner, U., Gustafsson, LL., Doua, F., Ericsson, O., Miezán, T., Rais, M., Rombo, L. (1995) Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with *Trypanosoma gambiense* sleeping sickness, *Br. J. Clin. Pharmacol.* 39(3), 289- 295

Butcher, B., Denkers (2002) Mechanism of entry determines the Ability of *Toxoplasma gondii* to inhibit macrophage proinflammatory cytokine production, *Infection and Immunity*, 70, 5216-5224

Carstensen, H., Müller, R.H., Müller, B.W. (1992) Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake, *Clinical Nutrition* 11, 289-297

Chardes, T., Bout, D. (1993) Mucosal immune response in toxoplasmosis, *Res. Immunol.* 144, 57

Couvreur, P., Kante, B., Grislain, L., Roland, M., Speiser, P. (1982) Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles, *J. Pharm. Sci.* 71, 790-792

Couvreur, P., Lenaerts, V., Leyh, D., Guiot, P., Roland, M. (1984) Design of biodegradable polyalkylcyanoacrylate nanoparticles as a drug carrier. In: Davis, S.S., Illum, L., Mc Vie, J.G., Tomlinson, E (eds) *Microspheres and drug therapy*. Amsterdam: Elsevier, 103-105

Cruz, T., Gaspar, R., Donato, A., Lopes, C. (1997) Interaction between polyalkylcyanoacrylate nanoparticles and peritoneal macrophages: MTT metabolism, NBT reduction, and NO production, *Pharm. Res.* 14(1), 73-79

Cudd, A., Noonan, C.A., Tosi, P.F., Melnick, J.L., Nicolau, C. (1990) Specific interaction of CD4-bearing liposomes with HIV-infected cells, *AIDS.* 3(2), 109-114

Däubener, W., Spors, B., Hucke, C., Adam, R., Stins, M., Kim, K. S., Schrotten, H. (2001) Restriction of *Toxoplasma gondii* growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase, *Infect. Immun.* 69, 6527

10. Literaturverzeichnis

- Diepold, R., Kreuter, J., Himber, J., Gurny, R., Lee, V.H.K., Robinson, J.R., Saettone, M.F., Schnaudigel, O.E. (1989) Comparison of different models for the testing of pilocarpine eye-drops using conventional eyedrops and a novel depot formulation (nanoparticles), *Greafe`s Arch. Clin. Exp. Ophthalmol.* 227, 188-193
- Douglas, S.J., Illum, L., Davis, S., Kreuter, J. (1984) Particles Size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles. I. Influence of physicochemical factors, *J. Colloid. Interface Sci.* 101, 149-158
- Douglas, S.J., Illum, L., Davis, S. (1985) Particles Size and size distribution of poly(butyl-2-cyanoacrylate) nanoparticles. II. Influence of stabilizers, *J. Colloid. Interface Sci.* 103, 154-163
- Douglas, S.J., Illum, L., Davis, S. (1986) Biodistribution of poly(butyl 2-cyanoacrylate) nanoparticles in rabbits, *Int. J. Pharm.* 34, 145-152
- Dubey, J.P., Lindsay, D.S., Speer, C.A. (1998) Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. *Clin Microbiol Rev* 11, 267-99
- Durand R, Paul M, Rivollet D, Fessi H, Houin R, Astier A, Deniau M. (1997) Activity of pentamidine-loaded poly(d,l-lactide) nanoparticles against *Leishmania infantum* in a murine model, *Parasite.* 4, 331–336
- EMA, Committee for Veterinary Medicinal Products (1995) Spiramycin (2) - Summary Report. European Agency for the Evaluation of Medicinal Products, London (GB)
- Enders, G. (1991) Toxoplasmose in der Schwangerschaft. In: P.M. Shah, W. Stille (Hrsg.): *Infektionen durch Toxoplasma gondii*. Socio-medico Verlag, Gräfelting; p. 33
- Endo, T., Sethi, K. K., Piekarski, G. (1982) *Toxoplasma gondii*: calcium ionophore A23187-mediated exit of trophozoites from infected murine macrophages, *Exp. Parasitol.* 53, 179-88

10. Literaturverzeichnis

- Fichera, M.E., Roos, D. S. (1997) A plastid organelle as a drug target in apicomplexan parasites, *Nature* 390, 407-409
- Fitch, R.M., Prenosil, M.B., Spricj, K.J. (1969) *J. Polym. Sci. C*, 27,95
- Fitch, R.M. (1973) The homogenous nucleation of polymer colloids, *Br. Polymer J.* 5, 467-483
- Friese, A., Seiller, E., Quack, G., Lorenz, B., Kreuter, J. (2000) Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. *Eur. J. Pharm. Biopharm.* 49 (2) 103-9
- Furtado, G.C., Cao, Y., Joiner, K.A. (1992) Laminin on *Toxoplasma gondii* mediates parasite binding to the beta 1 integrin receptor alpha 6 beta 1 on human foreskin fibroblasts and Chinese hamster ovary cells, *Infect. Immun.* 60, 4925
- Gamazo, C., Blanco-Prieto, M., Lecaroz, C., Vitas, A., Gander, B., Irache, J.M., Prior, S. (2004) New Therapeutic Approaches for the Treatment of Brucella Infections: Gentamicin Entrapment into Drug Delivery Systems, *Curr. Med. Chem. Anti-Canc Agents* 3, 43-56
- Gaspar, R., Opperdoes, F.R., Preat, V., Roland, M. (1992) Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular *Leishmania donovani*, *Ann. Trop. Med. Parasitol.* 86 (1) 41-49
- Gessner, A., Waicz, R., Lieske, A., Paulke, B.R., Mäder, K., Müller, R.H. (2000) Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption, *Int. J. Pharm.* 196, 245-249
- Gipps, E.M., Groscurth, P., Kreuter, J., Speiser, P. (1987) The effects of polyalkylcyanoacrylate nanoparticles on human normal and malignant mesenchymal cells in vitro, *Int. J. Pharm.* 40, 23-31
- Godofsky, E.W. (1994) Treatment of presumed cerebral toxoplasmosis with azithromycin, *N. Engl. J. Med.* 330, 575

10. Literaturverzeichnis

- Göppert, T. (2005) Plasmaproteinadsorption auf parenteral applizierbaren kolloidalen Arzneistoffträgern zur Überwindung der Blut-Hirn-Schranke, Dissertation Freie Universität Berlin
- Grigg, M.E., Bonnefoy, S., Hehl, A.B., Suzuki, Y., Boothroyd, J.C. (2001) Success and virulence in *Toxoplasma* as the result of sexual recombination between two distinct ancestries, *Science* 294, 161-165
- Gross, U. (1995) Neue Möglichkeiten der Toxoplasmose-Diagnostik. In: "Toxoplasmose - Erreger und Krankheit", Pohle, H. D.; Remington, J. S. (Hrsg.), Socio-medico Verlag, Gräfelfing, 2. Auflage, 78-111
- Gross, U., Lüder, C.G.K., Hendgen, V., Heeg, C., Sauer, I., Weidner, A., Krczal, D., Enders, G. (2000) Comparative IgG-antibody profile between mother and child (CGMC test) for diagnosis of congenital toxoplasmosis, *J. Clin. Microbiol.* 38, 3619–3622
- Gulyaev, A.E., Gelperina, S.E., Skidan, I.N. Antropov, A.S., Kivman, G.Y. Kreuter, J. (1999) Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles, *Pharm. Res.* 16 (10) 1564-1569
- Härtig, W., Paulke, B.-R., Brückner, G. (1992) Fluorescent latex microspheres for retrograde tracing of neurons in mouse basal forebrain combined with immunocytochemistry: a methodical approach, *Acta Histochem. Suppl.*, 42, 261-265
- Härtig, W., Paulke, B.-R., Varga, S., Seeger, J., Harkany, T., Kacza, J. (2003) „Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β -Amyloid in Alzheimer's disease, *Neuroscience Letters* 338, 174 – 176
- Henry-Michelland, S., Alonso, M.J., Andremont, A., Maincent, P., Sauzieres, J., Couvreur, P. (1987) Attachment of antibodies to nanoparticles: Preparation, drug release and antimicrobial activity *in vitro*, *Int. J. Pharm.* 35, 121-127
- Hergeth, W.D., Schmutzler, K. (1985) Polymerization in the presence of seeds, *Acta Polymerica* 36, 9, 472- 474

10. Literaturverzeichnis

- Hochstrasser, D.F., Harrington, M.E., Hochstrasser, A.-C., Merrill, C.R. (1988) Methods for increasing the resolution of two-dimensional protein electrophoresis, *Anal. Biochem.* 173, 424-435
- Illum, L., Khan, M.A., Mak, E., Davis, S.S. (1986) Evaluation of carrier capacity and release characteristics for poly(butyl 2-cyanoacrylate) nanoparticles, *Int. J. Phar.* 30, 17-28
- Illum, L., Davis, S.S. (1987) Targeting of colloidal particles to the bone marrow, *Life Sci.* 40, 1553-1560
- Illum, L., Davis, S.S., Müller, R.H., Mak, E., West, P. (1987a) The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908, *Life Sci.* 40(4) 367-374
- Jacquier, P., Deplazes, P., Heimann, P., Gottstein, B. (1995) Parasitologie und humanmedizinisch-präventive Bedeutung von *Toxoplasma gondii*, *Schweiz. Med. Wochenschr.* 125, Suppl. 65, 10-18
- Jacobasch, H.-J. (1984) Oberflächenchemie faserbildender Polymerer, Akademie-Verlag Berlin, 1984
- Jacobs, L., Remington, J.S., Melton, M. L. (1957) The resistance of the encysted form of *Toxoplasma gondii*, *J. Parasitol.* 46, 11-21
- Janitschke, K. (1991) Toxoplasmose. In: "Medizinische Mikrobiologie", Hahn, H.; Falke, D.; Klein, P. (Hrsg.), Springer Verlag, Berlin, Heidelberg, New York, 1991, 898-900
- Joiner, K.A., Roos, D.S. (2002) Secretory traffic in the eukaryotic parasite *Toxoplasma gondii*: less is more, *J. Cell Biol.* 157, 557
- Kante, B., Couvreur, P., Dubois-Krack, G., De Meester, C., Guiot, P., Roland, M., Mercier, M., Speiser, P. (1982) Toxicity of polyalkylcyanoacrylate nanoparticles I: Free nanoparticles, *J. Pharm. Sci.* 71(7) 786-790

10. Literaturverzeichnis

- Kayser, K., Zeilinger, C., Zeng, F. Y., Gabius, S., Gabius, H. J., & Weiser, W. Y. (1993) Detection of the lymphokine migration inhibitory factor in normal and disease-affected lung by antibody and by its major binding protein, the interferon antagonist sarcolectin, *Pathol.Res.Pract.* 189, 992-995
- Kopf, H., Joshi, R.K., Solvia, M., Speiser, P. (1976) Studium der Mizellpoymerisation in Gegenwart niedermolekularer Arzneistoffe. I. Herstellung und Isolierung der Nanopartikel, Restmonomerbestimmung, physikalisch-chemische Daten, *Pharm. Ind*, 38, 281 - 284
- Kovacs, J.A. and the NIAID-clinical center intramural AIDS program (1992) Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. *Lancet* 340, 637
- Kreuter, J., Speiser, P. (1976) New adjuvants on a polymethylmethacrylate base, *Infection and Immunity*, 13, 204-210
- Kreuter, J. (1983) Evaluation of Nanoparticles as Drug-Delivery Systems, I: Preparation Methods, *Pharm. Acta Helv.* 58, Nr. 7
- Kreuter, J. (1983a) Evaluation of Nanoparticles as Drug-Delivery Systems, III: Materials, stability, toxicity, possibility of targeting and use, *Pharm. Acta Helv.* 58, 242-250
- Kreuter, J., Nefzger, M., Liehl, E., Czok, R., Voges. (1983b) Distribution and elimination of poly(methyl methacrylate) nanoparticles after subcutaneous administration to rats, *J. Pharm. Sci.* 71, 1146-1149
- Kreuter, J. (1988) Possibilities of using nanoparticles as carriers for drugs and vaccines, *J microencaps.* 5 (2) 115-127
- Kreuter, J. (1994) *Colloidal Drug Delivery Systems*, M. Dekker, New York
- Kreuter, J. (1994a) Drug targeting with nanoparticles, *Eur. J. Drug Metab. Pharmacokinet.* Jul-Sep;19(3),253-6

10. Literaturverzeichnis

- Kreuter, J., Alyautdin, R.N., Kharkevich, D.A., Ivanov, A.A. (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles), *Brain Res.* 674 (1), 171-174
- Krewski, D., Burnett, R., Jerrett, M., Pope, C., Rainham, D., Calle, E., Thurston, G., Thun, M. (2005) Mortality and Long-Term Exposure to Ambient Air Pollution: Ongoing Analyses Based on the American Cancer Society Cohort, *J. Toxicol. Environ. Health. A*, 68 (13-14) 1093-1109
- Kroker R (1999) Pharmaka zur Behandlung und Verhütung bakterieller Infektionen
In: *Pharmakotherapie bei Haus- und Nutztieren*, Parey, Berlin, 211-246
- Leanaerts, V., Couvreur, P., Christiaens-Leyh, D., Joiris, E., Roland, M., Rollmann, B., Speiser, P. (1984) Degradation of poly(isobutylcyanoacrylate) nanoparticles, *Biomaterials* 5, 65
- Levine, N.D. (1977) Taxonomy of *Toxoplasma*, *J. Protozool.* 24, 36-40
- Lehr, C.-M., Gabor, F. (2004) Lectins and glycoconjugates in drug delivery and targeting, *Advanced Drug Delivery Reviews*, 56 (4), 419 - 420
- Leyke, S., Köhler-Sokolowska, W., Paulke, B.-R., Müller, R.H., Presber, W. (2005) Effects of Nanoparticles in cells infected by *Toxoplasma gondii*, *Eur. J. Pharm. Biopharm* (eingereicht)
- Lherm, C., Müller, R.H., Herbort, J., Brandes, G. (1989) Cytotoxicity of polyalcylycyanoacrylate particles of increasing chain length, *APGI-Kongreß, Paris, III* 81-88
- Lück, M., Paulke, B.-R., Schröder, W., Blunk, T., Müller, R.H. (1997) Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics, *J. Biomed. Mat. Res.*, 478-485
- Lück, M., Schröder, W., Paulke, B.R., Blunk, T., Müller, R.H. (1999) Complement activation by model drug carriers for intravenous application: determination by two-dimensional electrophoresis, *Biomaterials* 20, 2063-2068

10. Literaturverzeichnis

Maincent P., Le Verge R., Sado P., Couvreur P., Devissaguet J.P. (1986) Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles, *J. Pharm. Sci.* 75(10), 955-8

Mittelviehhaus, H. (1992) Toxoplasmose in der Augenheilkunde. In: "Infektionen durch Toxoplasma gondii", Shah, P. M.; Stille, W. (Hrsg.), Socio-medico Verlag, Gräfelfing, 2. Auflage, 53-64

Montoya, J.G., Liesenfeld, O. (2004). Toxoplasmosis, *Lancet.* 363, 9456, 1965 - 1976

Müller, R.H., Heinemann, S. (1989) Surface modelling of microparticles as parenteral systems with high tissue affinity, In: Gurny, R., Junginger, H.E., *Bioadhesion — Possibilities and Future Trends* (Wissenschaftliche Verlagsgesellschaft Stuttgart), 202–214

Müller, R.H., Lherm, C., Herbort, J., Couvreur, P. (1990) In vitro model for the degradation of alkylcyanoacrylate nanoparticles, *Biomaterials* 11, 590-595

Müller, R.H. (1991) Colloidal carriers for controlled drug delivery and targeting — modification, characterization and in vivo distribution, (CRC Press, Boca Raton), Wissenschaftliche Verlagsgesellschaft Stuttgart

Müller, R.H., Lherm, C., Herbort, J., Couvreur, P. (1991a) Propidium Iodide Loaded Polyalkylcyanoacrylate Particles - Labelling Conditions and Loading Capacity, *Colloid and Polym. Sci.* 269, 147-152

Müller, R.H., Lherm, C., Herbort, J., Blunk, T., Couvreur, P. (1992) Alkylcyanoacrylate Drug Carriers I: Physicochemical Characterization of Nanoparticles with Different Alkyl Chain Length, *Int. J. Pharm.* 84, 1-11

Müller, R.H., Wallis, K.H., Tröster, S.D., Kreuter, J. (1992a) In vitro characterization of poly(methyl methacrylate) nanoparticles and correlation to their in vivo fate, *J. Control. Rel.* 20, 237-246

10. Literaturverzeichnis

- Müller, R.H., Wallis, K.H. (1993) Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908, *Int. J. Pharm.* 89, 25-32
- Müller, R. H., Schuhmann, R. (1996) Teilchengrößenmessung in der Laborpraxis. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
- Müller, R.H. (1996a) Zetapotential und Partikelladung in der Laborpraxis, APV Paperback, Wissenschaftliche Verlagsgesellschaft Stuttgart
- Müller, R.H., Rühl, D., Lück, M., Paulke, B.-R. (1997) Influence of Fluorescent Labelling of Polystyrene Particles on Phagocytic Uptake, Surface Hydrophobicity and Plasma Protein Adsorption, *Pharmaceutical Research*. 14, 18 - 24
- Müller, R.H. (1997a) Surface Hydrophobicity - Determination by Rose Bengal (RB) Adsorption Methods, in: Müller, R. H., Mehnert, W. (Hrsg.), *Particle and Surface Characterisation Methods*, Wissenschaftliche Verlagsgesellschaft Stuttgart, 215-228
- Müller, R.H., Rühl, D., Schulze-Forster, K (1997b) Interaction of differentiated HL60 cells with poloxamer and poloxamine surface modified model drug carrier, *E. J. Pharm.Sci.* 5, 147-153
- Müller, R.H., Wissing, S. A., Radomska, A. (2001) Clinical batch production of peptide-loaded nanoparticles, *New Drugs* 1, 72-74
- Mutschler, E. (2001) *Arzneimittelwirkungen*. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 9. Auflage
- Nathan, C.F., Nogueira, N., Juangbhanich, C., Ellis, J., Cohn, Z (1979) Activation of macrophages in vivo and in vitro, *J. Exp. Med.* 149,1056-1068
- Nicolle, C., Manceaux, L. (1908) Sur une infection à corps de Leishman (ou organismes voisins) du gondi. *C. R. Acad. Sci. Paris.* 147, 763

10. Literaturverzeichnis

- Ockert, G. Epidemiologie der Toxoplasma-Infektion. In: "Toxoplasmose - Erreger und Krankheit", Pohle, H. D.; Remington, J. S. (Hrsg.), Socio-medico Verlag, Gräfelfing, 1995, 2. Auflage, 30-42
- Opitz, C., Soldati, D. (2002) The glideosome: a dynamic complex powering gliding motion and host cell invasion by *Toxoplasma gondii*, Mol. Microbiol. 45, 597-604
- Paulke, B.-R., Möglich, P.-M., Knippel, E., Budde, A., Nitzsche, R., Müller, R.H. (1995) Electrophoretic 3D-Mobility Profiles of Latex Particles with Different Surface Groups, Langmuir. 11, 70 - 74
- Päuser S, Reszka R, Wagner S, Wolf K., Buhr H., Berger G (1997) Liposome-encapsulated superparamagnetic iron oxide particles as markers in an MRI-guided search for tumorspecific drug carriers. Anticancer Drug Des. 12,125–135
- Pfefferkorn, E.R. (1990) Cell biology of *Toxoplasma gondii*. In: Modern Parasite Biology, Cellular, Immunological and Molecular Aspects. Wyler D.J., Freeman NY 26
- Remington, J.S., McLeod, R., (1986) Toxoplasmosis. In: "Infectious Diseases and Medical Microbiology", Braude, A. I.; Davis, C. E.; Fierer, J. (eds.), W. B. Saunders Company, Philadelphia, London, Toronto, 1986, 2nd edition, 1521-1535
- Reszka, R., Beck, P., Fichtner, I., Hentschel, M., Richter, R., Kreuter, J. (1997) Body Distribution of Free, Liposomal and Nanoparticle-Associated Mitoxantrone in B16-Melanoma-Bearing Mice, Pharmacology 280 (1) 232-237
- Riddick, T.M. (1968) Zeta-Meter Manual, Zeta-Meter Inc., New York
- Ruf, B. (1995) Therapie und Prophylaxe der Toxoplasmose. In: "Toxoplasmose - Erreger und Krankheit", Pohle, H. D.; Remington, J. S. (Hrsg.), Socio-medico Verlag, Gräfelfing, 2. Auflage, 195-234

10. Literaturverzeichnis

Saffer, L.D., Mercereau-Puijalon, O., Dubremetz, J.F., Schwartzman, J.D. (1992) Localization of a *Toxoplasma gondii* rhoptry protein by immunoelectron microscopy during and after host cell penetration, *J. Protozool.* 39, 526-30

Saupe, A. (2004) Pharmazeutisch-kosmetische Anwendungen Nanostrukturierter Lipidcarrier (NLC), Dissertation Freie Universität Berlin

Scherer, D. (1992) Einfluß von Polybutylcyanoacrylat-Nanopartikeln auf die orale Absorption von Arzneistoffen, PhD Thesis, Johann Wolfgang Goethe-Universität, Frankfurt am Main

Schlüter, D. (2004) Spiele, die Parasiten mit uns treiben, Lehren der Toxoplasmose, *Marburger Wissenschaftsjournal* 2, 21-28

Schöler, N., Krause, K., Kayser, O., Müller, R.H., Borner, K., Hahn, H., Liesenfeld, O. (2001) Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis, *Antimicrobial Agents and Chemotherapy*, 45 (6) 1771-1779

Schoondermark-Van de Ven E, Melchers W, Camps W, Eskes T, Meuwissen J, Galama, J. (1994) Effectiveness of spiramycin for treatment of congenital *Toxoplasma gondii* infection in rhesus monkeys, *Antimicrob. Agents. Chemother.* 38(9), 1930-6

Seitz, H. M. (1992) Mikrobiologie von Toxoplasma-Spezies. In: "Infektionen durch Toxoplasma gondii", Shah, P. M.; Stille, W. (Hrsg.), Socio-medico Verlag, Gräfelfing, 2. Auflage, 7-18

Seitz, H.M. (1995) Toxoplasma gondii: Mikrobiologische Aspekte. In: "Toxoplasmose - Erreger und Krankheit", Pohle, H. D.; Remington, J. S. (Hrsg.), Socio-medico Verlag, Gräfelfing, 2. Auflage, 43-52

Sibley, L.D., Weidner, E., Krahenbuhl, J. L. (1985) Phagosome acidification blocked by intracellular *Toxoplasma gondii*, *Nature* 315, 416-419

10. Literaturverzeichnis

- Sinai, A.P., Webster, P., Joiner, K.A. (1997) Association of host cell endoplasmic reticulum and mitochondria with the *Toxoplasma gondii* parasitophorous vacuole membrane: a high affinity interaction, *J. Cell. Sci.* 110, 2117-2128
- Sordet, F., Aumjaud, Y., Fessi, H., Derouin, F. (1998) Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis, *Parasite* 5, 223-9
- Steuber, S., Kroker, R. (1999) Antiprotozoika. In: *Pharmakotherapie bei Haus- und Nutztieren* (W Löscher, FR Ungemach & R Kroker, eds), Parey, Berlin (D), 355-377
- Tröster, S.D., Müller, U., Kreuter, J. (1990) Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants, *Int. J. Pharm.* 61, 85-100
- Tröster, S.D., Wallis, K.H., Müller, R.H., Kreuter, J. (1992) Correlation of the surface hydrophobicity of ¹⁴C-poly (methyl methacrylate) nanoparticles to their body distribution, *J. Control. Rel.* 20, 247-260
- Vauthier, C., Dubernet, C., Chauvierre, C., Brigger, I., Couvreur, P. (2003) Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles, *J. Control Release.* 93(2), 151-60
- Veizin, W.R., Florence, A.T. (1980) In vitro heterogeneous degradation of poly(n-alkyl acrylates), *J. Biomed. Mater. Res.* 14, 93-106
- Wallis, K.H., Müller, R.H. (1989) In Vitro Degradation Model for PLA, PLA/GA and PHB Nanoparticles, *Arch. Pharm.* 322, 769
- Wallis, K.H., Müller, R.H. (1990) Stabilität von Poloxamer und Poloxamine Coatingfilmen auf Polystyren Nanopartikeln, *Acta Pharm. Technol.* 36 (3), 127-132
- Weitschies W, Kötz R, Trahms L, Cordini, D. (1997) High resolution monitoring of the gastrointestinal transit of magnetically marked capsule, *J. Pharm. Sci.* 86, 1218–1222

10. Literaturverzeichnis

Wildführ, W. (1975) Der Erreger der Toxoplasmose - *Toxoplasma gondii* Nicolle und Man-
ceaux 1908. In: "Toxoplasmose. Ratgeber für Ärzte und Tierärzte", Wildführ, G.; Wildführ,
W. (Hrsg.), VEB Gustav Fischer Verlag, Jena, (1975), 1. Auflage, 15-45

Wildführ, G. (1975) Epidemiologie der Toxoplasmose. In: "Toxoplasmose. Ratgeber für Ärz-
te und Tierärzte", Wildführ, G.; Wildführ, W. (Hrsg.), VEB Gustav Fischer Verlag, Jena,
1975, 1. Auflage, 71-95

Wissing, S., Saupe, A., Müller, R.H. (2003) Nanostructured lipid carriers (NLC) for topical
use – an overview, *Eurocosmetics* 5, 14-17

Wong, S. Y., Remington, J. S. (1993) Biology of *Toxoplasma gondii*, *Aids* 7, 299-316